Home Cart Sign in  
Chemical Structure| 869363-13-3 Chemical Structure| 869363-13-3

Structure of MLN8054
CAS No.: 869363-13-3

Chemical Structure| 869363-13-3

MLN8054

CAS No.: 869363-13-3

MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM and exhibits more than 40-fold selective for Aurora A than Aurora B.

4.5 *For Research Use Only !

Cat. No.: A531108 Purity: 98+%

Change View

Size Price

US Stock

Global Stock

In Stock
50mg łÇÿÿ¶ÊÊ Inquiry Inquiry
100mg łËÍî¶ÊÊ Inquiry Inquiry
250mg łÍÇî¶ÊÊ Inquiry Inquiry
1g łÇÇóͶÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 50mg

    łÇÿÿ¶ÊÊ

  • 100mg

    łËÍî¶ÊÊ

  • 250mg

    łÍÇî¶ÊÊ

  • 1g

    łÇÇóͶÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MLN8054

CAS No. :869363-13-3
Formula : C25H15ClF2N4O2
M.W : 476.86
SMILES Code : O=C(O)C1=CC=C(NC2=NC=C3C(C4=CC=C(Cl)C=C4C(C5=C(F)C=CC=C5F)=NC3)=N2)C=C1
MDL No. :MFCD11840561
InChI Key :HHFBDROWDBDFBR-UHFFFAOYSA-N
Pubchem ID :11712649

Safety of MLN8054

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of MLN8054

epigenetics
DNA

Isoform Comparison

Biological Activity

Target
  • Aurora A

    Aurora A, IC50:4 nM

  • Aurora B

    Aurora B, IC50:172 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
IMR-32 1000 nM 24 hours Treatment with MLN8054 abolished autophosphorylation of Aurora-A at Thr288 (T288) and caused a concentration-dependent decrease in N-Myc protein levels. PMC4298657
IMR-5 1000 nM 24 hours Treatment with MLN8054 abolished autophosphorylation of Aurora-A at Thr288 (T288) and caused a concentration-dependent decrease in N-Myc protein levels. PMC4298657
HCT-116 colon tumor cells 0.25, 1, 4 µM 24 hours To evaluate the inhibitory effect of MLN8054 on Aurora A activity, results showed that MLN8054 inhibited Aurora A autophosphorylation at T288 PMC1820716
HCT-116 and PC-3 cells 1 µM 24 and 48 hours To evaluate the effect of MLN8054 on the cell cycle, results showed that MLN8054 treatment led to an increase in 4N cells, indicating cell cycle arrest at G2/M phase PMC1820716
Hs294T 1 µM 5 days Induced cellular senescence, reduced cell number PMC3569660
SK-Mel-2 1 µM 5 days Induced cellular senescence, reduced cell number PMC3569660
SK-Mel-5 1 µM 5 days Induced cellular senescence, reduced cell number PMC3569660
SK-Mel-28 1 µM 5 days Induced cellular senescence, reduced cell number PMC3569660
HEp2 cells 4 µM 18 hours Tested the effect of MLN8054 alone or in combination with Taxol on HEp2 cells, showing that MLN8054 can reduce Taxol resistance in USP7-depleted cells. PMC3619237
L929sAhFas cells 2.528 µM 1 hour Danusertib induces cytokinesis defects in L929sAhFas cells with an EC50 of 2.528 µM, but shows weak inhibition of necroptosis with an IC50 of 13.92 µM. PMC5833749

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice TH-MYCN mouse model of neuroblastoma oral 25 mg/kg Once daily for 5 days Treatment with MLN8054 resulted in a significant decrease in N-Myc protein levels in tumors and induced tumor regression and prolonged survival in the TH-MYCN mouse model of neuroblastoma. PMC4298657
Nude mice HCT-116 and PC-3 human tumor xenograft models Oral 3 × 10^6 cells/mouse (nude mice) and 10^6 cells/mice (NOD/SCID mice) Single injection, tumor growth monitored continuously To evaluate the in vivo antitumor activity of MLN8054, results showed that MLN8054 significantly inhibited tumor growth, and the tumor growth inhibition was sustained after treatment discontinuation PMC1820716
Mice Melanoma xenograft model Oral 3, 10, 30 mg/kg Once daily for 21 days Inhibited melanoma growth, induced tumor cell senescence PMC3569660

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00249301 Breast Neoplasm|Colon Neoplasm... More >>|Pancreatic Neoplasm|Bladder Neoplasm Less << PHASE1 TERMINATED - The Sarah Cannon Research Inst... More >>itute, Nashville, Tennessee, 37203, United States Less <<
NCT00652158 Advanced Malignancies PHASE1 TERMINATED 2025-04-08 Ciutat Sanitaria Vall d'Hebron... More >>, Barcelona, 08035, Spain Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.10mL

0.42mL

0.21mL

10.49mL

2.10mL

1.05mL

20.97mL

4.19mL

2.10mL

References

 

Historical Records

Categories